165 related articles for article (PubMed ID: 26545407)
1. Longitudinal Change in Mammographic Density among ER-Positive Breast Cancer Patients Using Tamoxifen.
Nyante SJ; Sherman ME; Pfeiffer RM; Berrington de Gonzalez A; Brinton LA; Bowles EJ; Hoover RN; Glass A; Gierach GL
Cancer Epidemiol Biomarkers Prev; 2016 Jan; 25(1):212-6. PubMed ID: 26545407
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of mammographic density change after initiation of tamoxifen for ER-positive breast cancer.
Nyante SJ; Sherman ME; Pfeiffer RM; Berrington de Gonzalez A; Brinton LA; Aiello Bowles EJ; Hoover RN; Glass A; Gierach GL
J Natl Cancer Inst; 2015 Mar; 107(3):. PubMed ID: 25663687
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant tamoxifen-induced mammographic breast density reduction as a predictor for recurrence in estrogen receptor-positive premenopausal breast cancer patients.
Ko KL; Shin IS; You JY; Jung SY; Ro J; Lee ES
Breast Cancer Res Treat; 2013 Dec; 142(3):559-67. PubMed ID: 24233999
[TBL] [Abstract][Full Text] [Related]
4. Effects of Tamoxifen and oestrogen on histology and radiographic density in high and low mammographic density human breast tissues maintained in murine tissue engineering chambers.
Chew GL; Huo CW; Huang D; Blick T; Hill P; Cawson J; Frazer H; Southey MC; Hopper JL; Britt K; Henderson MA; Haviv I; Thompson EW
Breast Cancer Res Treat; 2014 Nov; 148(2):303-14. PubMed ID: 25332094
[TBL] [Abstract][Full Text] [Related]
5. Mammographic density changes following discontinuation of tamoxifen in premenopausal women with oestrogen receptor-positive breast cancer.
Kim WH; Cho N; Kim YS; Yi A
Eur Radiol; 2018 Aug; 28(8):3176-3184. PubMed ID: 29626240
[TBL] [Abstract][Full Text] [Related]
6. Mammographic density reduction is a prognostic marker of response to adjuvant tamoxifen therapy in postmenopausal patients with breast cancer.
Li J; Humphreys K; Eriksson L; Edgren G; Czene K; Hall P
J Clin Oncol; 2013 Jun; 31(18):2249-56. PubMed ID: 23610119
[TBL] [Abstract][Full Text] [Related]
7. Baseline breast tissue characteristics determine the effect of tamoxifen on mammographic density change.
Gabrielson M; Hammarström M; Bergqvist J; Lång K; Rosendahl AH; Borgquist S; Hellgren R; Czene K; Hall P
Int J Cancer; 2024 Jul; 155(2):339-351. PubMed ID: 38554131
[TBL] [Abstract][Full Text] [Related]
8. The association of mammographic density with risk of contralateral breast cancer and change in density with treatment in the WECARE study.
Knight JA; Blackmore KM; Fan J; Malone KE; John EM; Lynch CF; Vachon CM; Bernstein L; Brooks JD; Reiner AS; Liang X; Woods M; ; Bernstein JL
Breast Cancer Res; 2018 Mar; 20(1):23. PubMed ID: 29566728
[TBL] [Abstract][Full Text] [Related]
9. Mammographic density change in a cohort of premenopausal women receiving tamoxifen for breast cancer prevention over 5 years.
Brentnall AR; Warren R; Harkness EF; Astley SM; Wiseman J; Fox J; Fox L; Eriksson M; Hall P; Cuzick J; Evans DG; Howell A
Breast Cancer Res; 2020 Sep; 22(1):101. PubMed ID: 32993747
[TBL] [Abstract][Full Text] [Related]
10. Minimal impact of adjuvant exemestane or tamoxifen treatment on mammographic breast density in postmenopausal breast cancer patients: a Dutch TEAM trial analysis.
van Nes JG; Beex LV; Seynaeve C; Putter H; Sramek A; Lardenoije S; Duijm-de Carpentier M; Van Rongen I; Nortier JW; Zonderland HM; van de Velde CJ
Acta Oncol; 2015 Mar; 54(3):349-60. PubMed ID: 25383451
[TBL] [Abstract][Full Text] [Related]
11. Mammographic Density Reduction as a Prognostic Marker for Postmenopausal Breast Cancer: Results Using a Joint Longitudinal-Survival Modeling Approach.
Andersson TM; Crowther MJ; Czene K; Hall P; Humphreys K
Am J Epidemiol; 2017 Nov; 186(9):1065-1073. PubMed ID: 28633324
[TBL] [Abstract][Full Text] [Related]
12. Mammographic density and risk of breast cancer by age and tumor characteristics.
Bertrand KA; Tamimi RM; Scott CG; Jensen MR; Pankratz V; Visscher D; Norman A; Couch F; Shepherd J; Fan B; Chen YY; Ma L; Beck AH; Cummings SR; Kerlikowske K; Vachon CM
Breast Cancer Res; 2013 Nov; 15(6):R104. PubMed ID: 24188089
[TBL] [Abstract][Full Text] [Related]
13. Circulating hormones and breast cancer risk in premenopausal women: a randomized trial of low-dose tamoxifen and fenretinide.
Johansson H; Bonanni B; Gandini S; Guerrieri-Gonzaga A; Cazzaniga M; Serrano D; Macis D; Puccio A; Sandri MT; Gulisano M; Formelli F; Decensi A
Breast Cancer Res Treat; 2013 Dec; 142(3):569-78. PubMed ID: 24241787
[TBL] [Abstract][Full Text] [Related]
14. Breast density change as a predictive surrogate for response to adjuvant endocrine therapy in hormone receptor positive breast cancer.
Kim J; Han W; Moon HG; Ahn S; Shin HC; You JM; Han SW; Im SA; Kim TY; Koo H; Chang J; Cho N; Moon W; Noh DY
Breast Cancer Res; 2012 Jul; 14(4):R102. PubMed ID: 22770227
[TBL] [Abstract][Full Text] [Related]
15. Mammographic Density Decline, Tamoxifen Response, and Prognosis by Molecular Characteristics of Estrogen Receptor-Positive Breast Cancer.
Abubakar M; Mullooly M; Nyante S; Pfeiffer RM; Aiello Bowles EJ; Cora R; Bodelon C; Butler E; Butcher D; Sternberg L; Troester MA; Weinmann S; Sherman M; Glass AG; Berrington de Gonzalez A; Gierach GL
JNCI Cancer Spectr; 2022 May; 6(3):. PubMed ID: 35583138
[TBL] [Abstract][Full Text] [Related]
16. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors.
Fisher B; Dignam J; Bryant J; DeCillis A; Wickerham DL; Wolmark N; Costantino J; Redmond C; Fisher ER; Bowman DM; Deschênes L; Dimitrov NV; Margolese RG; Robidoux A; Shibata H; Terz J; Paterson AH; Feldman MI; Farrar W; Evans J; Lickley HL
J Natl Cancer Inst; 1996 Nov; 88(21):1529-42. PubMed ID: 8901851
[TBL] [Abstract][Full Text] [Related]
17. Association between high-sensitivity C-reactive protein (hsCRP) and change in mammographic density over time in the SWAN mammographic density subcohort.
Makboon K; Gold EB; Harvey DJ; Butler LM; Habel LA
Cancer Causes Control; 2015 Mar; 26(3):431-42. PubMed ID: 25604866
[TBL] [Abstract][Full Text] [Related]
18. Mammographic density-a review on the current understanding of its association with breast cancer.
Huo CW; Chew GL; Britt KL; Ingman WV; Henderson MA; Hopper JL; Thompson EW
Breast Cancer Res Treat; 2014 Apr; 144(3):479-502. PubMed ID: 24615497
[TBL] [Abstract][Full Text] [Related]
19. Mammographic patterns as a predictive biomarker of breast cancer risk: effect of tamoxifen.
Atkinson C; Warren R; Bingham SA; Day NE
Cancer Epidemiol Biomarkers Prev; 1999 Oct; 8(10):863-6. PubMed ID: 10548313
[TBL] [Abstract][Full Text] [Related]
20. Tamoxifen and breast density in women at increased risk of breast cancer.
Cuzick J; Warwick J; Pinney E; Warren RM; Duffy SW
J Natl Cancer Inst; 2004 Apr; 96(8):621-8. PubMed ID: 15100340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
